(Date:11/6/2009)...LLEY, Calif., Nov. 6 Calbiotech, I...ll Business Innovative Research (SBIR) Phase I con...al command. Under terms of the agreement, Calbiote...or the diagnosis of Dengue virus. ,, Dengue ...s a major threat to military forces deployed to tr...
(Date:11/5/2009)...URG, Md., Nov. 5 GenVec,...al results for the third quarter ended September 3...n ($0.04 per share) for the three months ended Sep...lion ($0.08 per share) in the comparable quarter o...09, GenVec,s net loss was $14.1 million ($0.15 per...
(Date:11/5/2009)...e Call on Thursday, November 5, 2009 at 4:30 p.m. ... 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceutic... OGXI ) today reported unaudited financial results...mber 30, 2009 and reviewed the Company,s highlight...ng consolidated results reflect the operations of ...
(Date:11/5/2009)..., CA, November 5, 2009 S...n using proprietary taste receptor-based technolog...ood, beverage, and ingredient supply industries, t...ncial results for the third quarter ended Septembe...ird quarter of 2009, compared to $4.0 million for ...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14...raTag(TM) technology,s ability to ...ANCISCO, Calif., May 16 Monogram,Biosciences, Inc...,collaborators will present results on HERmark(TM)...o measure HER2 and predict response to,Herceptin(R... cancer at the,upcoming 44th ASCO Annual Meeting t...
...r Aqua Bounty to scale back commitment to i... TSX symbol: SBS, CALGARY, May 1...,(TSX:SBS), a biotechnology company developing a p... cardiovascular diseases, today announced that,its... shrimp feed additive,program, Aqua Bounty Technol...
...oration,announced today that it has enrolled and r... IIb trial with oral larazotide acetate, an inhibi...atment of patients with active,celiac disease (CD)...d,placebo-controlled study will evaluate the clini...lity of larazotide acetate in 106 active CD,subjec...
Other Biology Technology:Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 2Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 3Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 4Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 5SemBioSys provides update on shrimp feed additive, Immunosphere(TM) 2SemBioSys provides update on shrimp feed additive, Immunosphere(TM) 3Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease 2Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease 3(Date:11/4/2009)...r 4, 2009 Childhood obesity in the United States ...ne fourth of advertising on daytime and prime time...tinuing questions about the role television plays ... of the Journal of Nutrition Education and Behavi...n might be a large contributor to the problem. , ...
(Date:11/4/2009)...ry that deciphered the DNA codes, or genomes, of t...has joined The Genome 10K Project, an internationa...sequences on 10,000 species of animals for conduct...can not be achieved. , Participating in The Geno...the Nov. 5, 2009 issue of the Journal of Heredity...
(Date:11/4/2009)...lif., Oct. 19 Spectros, developer ... imaging devices which shed light on life-threaten...xclusive distribution deals for both its T-Stat...covered include Australia, New Zealand, The Nethe...taly, France, Spain, Portugal, Poland, Greece, Tur...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 1TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 2TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 3TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 4Organogenesis Launches Regenerative Medicine College Scholarship 48514 1Organogenesis Launches Regenerative Medicine College Scholarship 48514 2Organogenesis Launches Regenerative Medicine College Scholarship 48514 3Gene Can Dampen Chemo Drug Effectiveness 48510 1Cassette, Hind III from Takara Mirus Bio
Cassette, EcoR I from Takara Mirus Bio
EcoR I Adaptors from Promega
Cassette, Sal I from Takara Mirus Bio
Biology Products: